Sep 13, 2024 | Cancer, Health care costs, Heart disease, High-cost claims, Mental Health, Rx Costs, Survey
Employers say they expect their health care costs to rise 7.8% next year — the highest estimate in more than 15 years — according to the latest Business Group on Health member survey. Even factoring in cost-reducing plan design changes, respondents project costs to...
Sep 3, 2024 | Biosimilars, Cost Savings, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Savings, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
Jul 5, 2024 | Biosimilars, Cost Savings, Humira, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Jul 3, 2024 | Flexible spending accounts (FSAs), Health reimbursement arrangements (HRAs), ID Card, MedBen Access, Mobile App, Rx Costs, Wellness compliance
If your plan members haven’t downloaded the MedBen Access mobile app, they’re missing out! Not only does the app provide timely claims and benefits information, it offers a variety of tools to help members better manage their benefits. Drug pricing...
Apr 16, 2024 | Biosimilars, Cost Savings, Drug costs, Humira, MedBen Rx, Pharmacy, Prescription, Rx Costs, Savings
Last year, MedBen Rx announced a new program that would enable clients to purchase Idacio, a biosimilar version of the anti-inflammatory therapy Humira – a drug that typically costs between $6,000 and $12,000 per month depending on the dose – for under $1,000 per...
Apr 1, 2024 | Benefits preservation, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Rx Costs, Savings, Specialty Drugs, Transparency
Employers are turning away from the “big three” pharmacy benefits managers to other PBMs that offer greater transparency and lower costs, says Wharton professor of health care management Lawton Robert Burns. As one of those alternatives, MedBen Rx is...
